A
ADC THERAPEUTICS SA
NYSE: ADCT (ADC Therapeutics SA)
Kemas kini terakhir: 3 jam lalu1.96
-0.16 (-7.55%)
| Penutupan Terdahulu | 2.12 |
| Buka | 2.07 |
| Jumlah Dagangan | 1,895,521 |
| Purata Dagangan (3B) | 792,867 |
| Modal Pasaran | 189,511,616 |
| Harga / Jualan (P/S) | 2.53 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Mar 2025 - 25 Mar 2025 |
| Margin Keuntungan | -300.00% |
| Margin Operasi (TTM) | -192.61% |
| EPS Cair (TTM) | -2.39 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 27.40% |
| Nisbah Semasa (MRQ) | 4.92 |
| Aliran Tunai Operasi (OCF TTM) | -133.62 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -96.83 M |
| Pulangan Atas Aset (ROA TTM) | -21.17% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | ADC Therapeutics SA | Bercampur | Menaik |
AISkor Stockmoo
1.5
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | 3.0 |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | 1.50 |
|
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 20.64% |
| % Dimiliki oleh Institusi | 61.60% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Redmile Group, Llc | 30 Sep 2024 | 15,669,217 |
| Prosight Management, Lp | 30 Sep 2024 | 9,636,237 |
| Orbimed Advisors Llc | 30 Sep 2024 | 4,533,801 |
| Silverarc Capital Management, Llc | 30 Sep 2024 | 1,795,080 |
| Platinum Investment Management Ltd | 30 Sep 2024 | 1,444,516 |
| Siren, L.L.C. | 30 Sep 2024 | 1,163,461 |
| Vantage Consulting Group Inc | 30 Sep 2024 | 850,737 |
| Blue Owl Capital Holdings Lp | 30 Sep 2024 | 733,568 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 10.00 (Guggenheim, 410.20%) | Beli |
| Median | 8.00 (308.16%) | |
| Rendah | 6.00 (Stephens & Co., 206.12%) | Beli |
| Purata | 8.00 (308.16%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 2.46 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Guggenheim | 12 Dec 2024 | 10.00 (410.20%) | Beli | 1.98 |
| Stephens & Co. | 08 Nov 2024 | 6.00 (206.12%) | Beli | 2.93 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| REDMILE GROUP, LLC | 2.22 | - | 100,000 | 222,000 |
| Jumlah Keseluruhan Kuantiti Bersih | 100,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 222,000 | |||
| Purata Pembelian Keseluruhan ($) | 2.22 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| REDMILE GROUP, LLC | 11 Dec 2024 | Beli (+) | 100,000 | 2.22 | 222,000 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |